PI3-kinase inhibitors in chronic lymphocytic leukemia

Keyphrases

• Chronic Lymphocytic Leukemia 100%
• PI3K Inhibitor 100%
• Idelalisib 50%
• Phosphatidylinositol 3-kinase Inhibitor 50%
• High Risk 25%
• Pneumonia 25%
• Response Rate 25%
• Phosphoinositide 3-kinase (PI3K) 25%
• Chemotherapy Resistance 25%
• Effective Therapy 25%
• Combination Chemotherapy 25%
• Tolerability 25%
• Chemotherapy Regimen 25%
• B-cell Receptor Signaling 25%
• Objective Response 25%
• Phosphatidylinositol 3-kinase Pathway 25%
• Clinical Activity 25%
• Leukocyte Trafficking 25%
• Combination Regimen 25%
• Pneumonitis 25%
• Drug-induced 25%
• Resistant Disease 25%
• Inhibitor Combination 25%
• Lymphocytosis 25%
• 17p Deletion 25%
• Transaminitis 25%
• B-cell Lymphoproliferative Disorder 25%
• Nodal Response 25%
• CAL-101 25%
• GS-1101 25%
• 11q Deletion 25%

Medicine and Dentistry

• B-Cell Chronic Lymphocytic Leukemia 100%
• Phosphoinositide 3-Kinase Inhibitor 100%
• Phosphoinositide 3-Kinase 50%
• Idelalisib 50%
• B Cell 25%
• Disease 25%
• Combination Chemotherapy 25%
• Elevated Transaminases 25%
• B Lymphocyte Receptor 25%
• Lymphoproliferative Disease 25%
• Pneumonia 25%
• Lymphocytosis 25%
• Chemotherapy Regimens 25%
• Lymphocyte 25%
• Chemotherapy 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 100%
• Phosphatidylinositol 3 Kinase Inhibitor 100%
• Phosphatidylinositol 3 Kinase 50%
• Idelalisib 50%
• Disease 25%
• Chemotherapy 25%
• Hypertransaminasemia 25%
• Tolerability 25%
• Chemotherapy Regimens 25%
• B Lymphocyte Receptor 25%
• Pneumonia 25%
• Lymphoproliferative Disease 25%
• Lymphocytosis 25%